- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02853461
Biofilm Investigation on Bearing Components of Explanted Hip Joint Prosthesis
Biofilm Investigation on Ceramic, Metal and Polyethylene Bearing Components From Explanted Hip Joint Prosthesis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main reasons for hip prosthesis failure are aseptic loosening and periprosthetic joint infection (PJI). The real frequency of PJI is probably largely underestimated because of non-standardized definition criteria, diagnostic procedure, treatment algorithm and other confounders. Therefore, data from joint registries are not reflecting the frequency of PJI and can be misleading; particularly low-grade PJI can be frequently misdiagnosed as aseptic failure.
Microbiological analysis of sonicate has in comparison with joint aspirate significantly higher sensitivity and specificity, which allows better detection of low grade infection. With aspiration only free-floating, high metabolically active, planktonic form of bacteria could be collected. Contrarily, the less metabolically active bacteria are hidden under the biofilm can remain undetected.
Sonication of prosthetic material mechanically dislodge the biofilm from surface and expose the sessile bacteria for the microbiological analysis.
All foreign materials provoke biofilm formation however, different materials showed different resistance for biofilm adhesion.
In this study patients with PJI are undergoing standard one- or two- stage revision procedure of the hip. The removed bearing components will be sonicated and sent in microbiological analysis. The ceramic, metal and polyethylene prosthesis components will undergo qualitative and quantitative microbiological analysis. The materials will be compared regarding to the presence of biofilm formation.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Recruiting
- Charité Universitätsmedizin Berlin
-
Contact:
- Andrej Trampuz, MD
- Phone Number: +49 30 450 615 073
- Email: andrej.trampuz@charite.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject must be aged 18 or more.
- Subject must be scheduled to undergo an explanation of the hip endoprosthesis during the 1- or 2- stage revision procedure because of the septic or mechanical indication.
- Subject must personally sign and date the informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Exclusion Criteria:
- Patient not scheduled for the index Operation procedure with removal of hip endoprosthesis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative analysis of sonication fluid after sonication of explanted bearing components of the hip endoprosthesis during a revision surgery
Time Frame: Prospective: patient recruitment up to 2 years
|
Qualitative Analysis, i.e. frequency of positive sonication fluid cultures (No. positive/No. all cultures) deriving from 3 different biomaterials (namely: Ceramic, Cobalt-chrome-metal, and Polyethylene), the number of variables which will be evaluated following: bearing component and its material (Ceramic, Cobalt-chrome-metal, and Polyethylene). All three material types will be compared between each other regard to microbiology analysis of sonication fluid of bearing components. |
Prospective: patient recruitment up to 2 years
|
|
Quantitative Analysis e.g. No. of microorganisms in sonication fluid (CFU/ml) deriving from 3 different biomaterials (namely: Ceramic, Cobalt-chrome-metal, and Polyethylene).
Time Frame: Prospective: patient recruitment up to 2 years
|
Prospective: patient recruitment up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Amount of patients with septic loosening of hip joint
Time Frame: Prospective: patient recruitment up to 2 years
|
Prospective: patient recruitment up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrej Trampuz, MD, Charite University, Berlin, Germany
Publications and helpful links
General Publications
- Achermann Y, Vogt M, Leunig M, Wust J, Trampuz A. Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fluid from removed implants. J Clin Microbiol. 2010 Apr;48(4):1208-14. doi: 10.1128/JCM.00006-10. Epub 2010 Feb 17.
- Banche G, Allizond V, Bracco P, Bistolfi A, Boffano M, Cimino A, Brach del Prever EM, Cuffini AM. Interplay between surface properties of standard, vitamin E blended and oxidised ultra high molecular weight polyethylene used in total joint replacement and adhesion of Staphylococcus aureus and Escherichia coli. Bone Joint J. 2014 Apr;96-B(4):497-501. doi: 10.1302/0301-620X.96B4.32895.
- Gomez-Barrena E, Esteban J, Medel F, Molina-Manso D, Ortiz-Perez A, Cordero-Ampuero J, Puertolas JA. Bacterial adherence to separated modular components in joint prosthesis: a clinical study. J Orthop Res. 2012 Oct;30(10):1634-9. doi: 10.1002/jor.22114. Epub 2012 Mar 30.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Endo 015/15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Total Hip Replacement
-
Ottawa Hospital Research InstituteThe Ottawa Hospital Academic Medical AssociationCompletedTotal Hip Replacement | Total Knee ReplacementCanada
-
Concentra AI, incRecruitingTotal Hip Replacement | Total Knee ReplacementUnited States
-
Ortho Development CorporationOregon Health and Science UniversityEnrolling by invitationTotal Hip Replacement | Total Hip ArthroplastyUnited States
-
The Royal Bournemouth HospitalCompletedArthroplasty, Replacement, Hip | Hip Replacement, TotalUnited Kingdom
-
National Taiwan University HospitalUnknownTotal Hip Replacement | Total Hip ArthroplastyTaiwan
-
Mayo ClinicCompletedKnee Total Joint Replacement | Hip Total Joint ReplacementUnited States
-
Musgrave Park HospitalBelfast Health and Social Care Trust; Queen's University, Belfast; Belfast Arthroplasty...CompletedTotal Hip Replacement | Total Hip Arthroplasty | THA | THRUnited Kingdom
-
ElsanNot yet recruitingPrimary Total Hip Arthroplasty | Primary Total Hip ReplacementFrance
-
University Hospital, CaenCompleted
-
Fondazione Don Carlo Gnocchi OnlusCompletedTotal Hip Replacement
Clinical Trials on Sonication
-
Bezmialem Vakif UniversityUnknownProsthesis-Related Infections | Joint Infection | Hip Prosthesis Infection | BiofilmTurkey
-
The University of Texas Health Science Center,...WithdrawnDepressive Disorder, MajorUnited States
-
InSightecCompletedUterine Fibroids | Uterine LeiomyomaUnited States, Canada
-
Columbia UniversityFocused Ultrasound FoundationTerminatedDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Pontine and Thalamic GliomasUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI); CarTheraActive, not recruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
Columbia UniversityFocused Ultrasound FoundationRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-MutantUnited States